404 related articles for article (PubMed ID: 19528089)
21. Unraveling the epigenetic code of cancer for therapy.
Smith LT; Otterson GA; Plass C
Trends Genet; 2007 Sep; 23(9):449-56. PubMed ID: 17681396
[TBL] [Abstract][Full Text] [Related]
22. [[Inhibitors of histone deacetylase as new agents for prevention and treatment of cancer] ].
Jung M
Pharm Unserer Zeit; 2000 Nov; 29(6):385-8. PubMed ID: 11199916
[No Abstract] [Full Text] [Related]
23. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.
Santini V; Gozzini A; Ferrari G
Curr Drug Metab; 2007 May; 8(4):383-93. PubMed ID: 17504226
[TBL] [Abstract][Full Text] [Related]
24. Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy.
Piekarz RL; Sackett DL; Bates SE
Cancer J; 2007; 13(1):30-9. PubMed ID: 17464244
[TBL] [Abstract][Full Text] [Related]
25. Creating zinc monkey wrenches in the treatment of epigenetic disorders.
Kalin JH; Butler KV; Kozikowski AP
Curr Opin Chem Biol; 2009 Jun; 13(3):263-71. PubMed ID: 19541531
[TBL] [Abstract][Full Text] [Related]
26. Development of curcumin as an epigenetic agent.
Fu S; Kurzrock R
Cancer; 2010 Oct; 116(20):4670-6. PubMed ID: 20597137
[TBL] [Abstract][Full Text] [Related]
27. DNA methyltransferase inhibitors for cancer therapy.
Brueckner B; Kuck D; Lyko F
Cancer J; 2007; 13(1):17-22. PubMed ID: 17464242
[TBL] [Abstract][Full Text] [Related]
28. [Epigenetics in hematological disorders].
Furukawa Y
Rinsho Ketsueki; 2008 Oct; 49(10):1472-82. PubMed ID: 18833931
[No Abstract] [Full Text] [Related]
29. Histone deacetylase inhibitor and demethylating agent chromatin compaction and the radiation response by cancer cells.
Bar-Sela G; Jacobs KM; Gius D
Cancer J; 2007; 13(1):65-9. PubMed ID: 17464248
[TBL] [Abstract][Full Text] [Related]
30. Inflammatory signalling as mediator of epigenetic modulation in tissue-specific chronic inflammation.
Bäckdahl L; Bushell A; Beck S
Int J Biochem Cell Biol; 2009 Jan; 41(1):176-84. PubMed ID: 18793748
[TBL] [Abstract][Full Text] [Related]
31. Epigenetic modifiers: basic understanding and clinical development.
Piekarz RL; Bates SE
Clin Cancer Res; 2009 Jun; 15(12):3918-26. PubMed ID: 19509169
[TBL] [Abstract][Full Text] [Related]
32. Cancer treatment of the future: inhibitors of histone methyltransferases.
Spannhoff A; Sippl W; Jung M
Int J Biochem Cell Biol; 2009 Jan; 41(1):4-11. PubMed ID: 18773966
[TBL] [Abstract][Full Text] [Related]
33. Epigenetic therapy for myelodysplastic syndromes has entered center stage.
Lübbert M
Leuk Res; 2009 Dec; 33 Suppl 2():S27-8. PubMed ID: 20004795
[No Abstract] [Full Text] [Related]
34. Epigenetic mechanisms in glioblastoma multiforme.
Nagarajan RP; Costello JF
Semin Cancer Biol; 2009 Jun; 19(3):188-97. PubMed ID: 19429483
[TBL] [Abstract][Full Text] [Related]
35. Promising strategies: Combination of epigenetic inhibitors for cancer therapy.
Gronemeyer H
Int J Cancer; 2020 Nov; 147(10):2656-2657. PubMed ID: 32599650
[No Abstract] [Full Text] [Related]
36. What is the potential of epigenetics in drug development?
Lundstrom K
Future Med Chem; 2015; 7(3):239-42. PubMed ID: 25826357
[No Abstract] [Full Text] [Related]
37. Making bad cells go good: the promise of epigenetic therapy.
Sausville EA; Carducci MA
J Clin Oncol; 2005 Jun; 23(17):3875-6. PubMed ID: 15946932
[No Abstract] [Full Text] [Related]
38. Epigenetics and complex disease: from etiology to new therapeutics.
Ptak C; Petronis A
Annu Rev Pharmacol Toxicol; 2008; 48():257-76. PubMed ID: 17883328
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic therapy for solid tumors: from bench science to clinical trials.
Juo YY; Gong XJ; Mishra A; Cui X; Baylin SB; Azad NS; Ahuja N
Epigenomics; 2015; 7(2):215-35. PubMed ID: 25942532
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic opportunities and challenges in cancer.
Best JD; Carey N
Drug Discov Today; 2010 Jan; 15(1-2):65-70. PubMed ID: 19897050
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
